` IPCI (Intellipharmaceutics International Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

IPCI
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, IPCI has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +28% growth.

Stocks Performance
IPCI vs S&P TSX Composite Index (Canada)

Loading
IPCI
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
IPCI vs S&P TSX Composite Index (Canada)

Performance Gap Between IPCI and GSPTSE
HIDDEN
Show

Performance By Year
IPCI vs S&P TSX Composite Index (Canada)

Loading
IPCI
S&P TSX Composite Index (Canada)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Intellipharmaceutics International Inc vs Peers

S&P TSX Composite Index (Canada)
IPCI
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Intellipharmaceutics International Inc
Glance View

Market Cap
2.6m CAD
Industry
Pharmaceuticals

Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company is headquartered in Etobicoke, Ontario. The firm is specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products and product candidates in various stages of development, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its Paradoxical OverDose Resistance Activating System (PODRAS) delivery technology is designed to prevent overdose when more pills than prescribed are swallowed intact. Its product and product candidates include Generic Focalin XR, Generic Keppra XR, Generic Glucophage XR and Generic Effexor XR, among others.

IPCI Intrinsic Value
Not Available
Back to Top